Raw Material Supply Chain Security for Cell and Gene Therapies: Guidance and best practices from Rx-360 industry consortium

Cells attacking cancer cells

Cell therapies, including CAR-T and TCR-T, and gene therapies will offer transformative outcomes for challenging diseases.

The need for unmet treatment options and the promise of cell therapies and gene therapies has prompted regulatory agencies around the world to develop accelerated review pathways. Shortened development timelines in response to global demand has added to the challenges associated with producing these novel treatments.

Industry experts from Avantor and leading pharmaceutical organizations collaborated on guidance and best practices for raw material supply chain management in a recent report developed and released by Rx-360, a consortium of manufacturers and suppliers from the pharmaceutical and biotech industries focusing on enhancing the security and consistency of the global pharma supply chain.

Download the full article

Solutions for bioprocessing

From the small-scale bench to full commercial manufacturing, we enable our customers to reach the market with new treatments for patients, faster and safer. Learn more about our offering for biopharmaceutical manufacturing.

Customer support

Contact us

Ready to streamline your bioprocessing manufacturing workflows? Avantor Biopharma Production can help.

Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world.